Search results
Results From The WOW.Com Content Network
Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost ...
But good news for Roche is bad news for the companies that now seem to have the weight-loss drug market to themselves. Shares of Eli Lilly (NYSE: LLY) were down 2.8% today, and Novo Nordisk (NYSE ...
Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index, after the company presented details on the trial with once-daily pill CT-996 late on ...
Roche's lawsuit, filed in July, said the biosimilar would infringe several patents related to the manufacture and use of its biologic drug. Biogen and Bio-Thera did not respond to the allegations ...
Judge Louis Stanton dismissed the privacy concerns as "speculative", and ordered YouTube to hand over documents totaling about 12 terabytes of data. [12] On the other hand, Stanton rejected Viacom's request that YouTube hand over the source code of its search engine, saying that it was a trade secret.
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.
(Reuters) -Roche shares gained as much as 4.7% on Thursday after an early-stage trial showed that a newly-acquired obesity drug candidate led to significant weight loss, a key step in Swiss ...
Roche on Friday announced another extension of its $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer ...